Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathryn A Gold

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Expert Opinion on Investigational Drugs|November 26, 2013
Afatinib in the treatment of head and neck squamous cell carcinomaRenata Ferrarotto, Kathryn A Gold
Current Opinion in Oncology|April 7, 2009
Role of molecular markers and gene profiling in head and neck cancersKathryn A Gold, Edward S Kim
Translational Lung Cancer Research|December 3, 2015
New strategies in immunotherapy for non-small cell lung cancerDaniel R Carrizosa, Kathryn A Gold
Oncology (Williston Park, N.Y.)|January 12, 2019
Immunotherapeutic Approaches to the Management of Head and Neck CancerXinyu Nan, Kathryn A Gold, Ezra Cohen
Expert Opinion on Investigational Drugs|June 26, 2012
Sorafenib in non-small cell lung cancerJianjun Zhang, Kathryn A Gold, Edward Kim
Otolaryngologic Clinics of North America|August 6, 2013
The role of systemic treatment before, during, and after definitive treatmentKathryn A Gold, Michele Neskey, William N William
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 21, 2021
Biotin-induced thyroid stimulating hormone aberrations in the setting of immunotherapyForrest N Ridgway, Kathryn A Gold, Linda C Barnachea
Cancer|January 22, 2009
Targeted therapies in squamous cell carcinoma of the head and neckKathryn A Gold, Ho-Young Lee, Edward S Kim
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2012
New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapyKathryn A Gold, Ignacio I Wistuba, Edward S Kim
Topics in Current Chemistry|August 2, 2012
Natural-agent mechanisms and early-phase clinical developmentJanet L Wang, Kathryn A Gold, Scott M Lippman
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Expert Opinion on Investigational Drugs|November 26, 2013
Afatinib in the treatment of head and neck squamous cell carcinomaRenata Ferrarotto, Kathryn A Gold
Current Opinion in Oncology|April 7, 2009
Role of molecular markers and gene profiling in head and neck cancersKathryn A Gold, Edward S Kim
Translational Lung Cancer Research|December 3, 2015
New strategies in immunotherapy for non-small cell lung cancerDaniel R Carrizosa, Kathryn A Gold
Oncology (Williston Park, N.Y.)|January 12, 2019
Immunotherapeutic Approaches to the Management of Head and Neck CancerXinyu Nan, Kathryn A Gold, Ezra Cohen
Expert Opinion on Investigational Drugs|June 26, 2012
Sorafenib in non-small cell lung cancerJianjun Zhang, Kathryn A Gold, Edward Kim
Otolaryngologic Clinics of North America|August 6, 2013
The role of systemic treatment before, during, and after definitive treatmentKathryn A Gold, Michele Neskey, William N William
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 21, 2021
Biotin-induced thyroid stimulating hormone aberrations in the setting of immunotherapyForrest N Ridgway, Kathryn A Gold, Linda C Barnachea
Cancer|January 22, 2009
Targeted therapies in squamous cell carcinoma of the head and neckKathryn A Gold, Ho-Young Lee, Edward S Kim
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2012
New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapyKathryn A Gold, Ignacio I Wistuba, Edward S Kim
Topics in Current Chemistry|August 2, 2012
Natural-agent mechanisms and early-phase clinical developmentJanet L Wang, Kathryn A Gold, Scott M Lippman
Pageof 5